trending Market Intelligence /marketintelligence/en/news-insights/trending/I3gswYuG-3r6s8X4cEesGg2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

The VC Beat: Kyverna Therapeutics gets $25M; Zipari lands $22.5M in financing

Banking Essentials Newsletter December Edition Part 2

Banking Essentials Newsletter - November Edition

University Essentials | COVID-19 Economic Outlook in Banking: Rates and Long-Term Expectations: Q&A with the Experts

Estimating Credit Losses Under COVID-19 and the Post-Crisis Recovery

The VC Beat: Kyverna Therapeutics gets $25M; Zipari lands $22.5M in financing

This feature rounds up venture capital news and highlights larger deal coverage already published.

* Cell therapy company Kyverna Therapeutics, which engineers a new class of autoimmune disease therapies, secured $25 million in series A funding from Vida Ventures, Westlake Village BioPartners and Gilead Sciences Inc.

* A $22.5 million series B financing round for health insurance consumer platform Zipari Inc. was led by Vertical Venture Partners, with participation from Health Velocity Capital; CareFirst BlueCross BlueShield's healthcare investment and innovation unit, Healthworx; and Horizon Healthcare Services Inc.

* Balderton Capital led a €12.7 million funding round for U.K.-based flexible business school Jolt, EU-Startups reported.

Additional coverage

Biopharma firm Transcenta raises US$100M in financing round

Nference raises $60M in 2nd round of financing for biomedical platform

Unless otherwise noted, historical funding data is sourced from the S&P Global Market Intelligence platform.